SBD111

About Solarea Bio

Solarea Bio is a private, preclinical-stage biotech leveraging the microbiome to develop dietary and therapeutic interventions for chronic diseases. Its most advanced asset, SBD111, has generated clinical data showing an ability to slow bone loss, pending peer review, positioning it in the large osteoporosis market. The company employs a platform approach to discover and develop microbial strains for specific dietary needs related to autoimmune and aging-related conditions, aiming for its first product launch in July 2025.

Therapeutic Areas